Restructuring, Strategic Transaction and Integration (Notes)

12 Months Ended

Dec. 31, 2021

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

RESTRUCTURING, STRATEGIC TRANSACTION AND INTEGRATION

Restructuring, strategic transaction and integration expenses were $18.0 million, $28.4 million and $80.6 million in 2021, 2020 and 2019, respectively.

Restructuring

Restructuring charges were $(1.8) million, $7.9 million and $8.4 million in 2021, 2020 and 2019, respectively, and are included in the above restructuring, strategic transaction and integration expenses in our consolidated statement of operations.

In 2021, we adjusted certain facility restructuring liabilities by $2.0 million, shown in the table below under "Other adjustments," to reflect actual amounts owed which resulted in net restructuring credits of $(1.8) million.

In 2020, restructuring charges were primarily related to severance and costs related to office and other facility closures.

In 2019, restructuring charges were primarily related to severance and facility closure costs. These charges were primarily related to a one-time charge to move our U.S. pump service depot to our existing Salt Lake City facility and other plant restructuring.

In 2015, we incurred restructuring charges related to an agreement with Dr. Lopez, a member of our Board of Directors and a former employee in our research and development department, pursuant to which we bought out Dr. Lopez's right to employment under his then-existing employment agreement. The buy-out, including payroll taxes, was paid in equal monthly installments until December 2020. This has been fully paid as of December 31, 2020.

The following table summarizes the activity in our restructuring-related accrual by major type of cost (in thousands):

	Severance Pay and Benefits		Employment Agreement Buyout		Retention and Facility Closure Costs		Total
Accrued balance, January 1, 2020	$	3,878	$	460	$	1,211	$	5,549
Charges incurred	4,288		—		3,641		7,929
Payments	(6,331)		(460)		(3,570)		(10,361)
Currency translation	23		—		281		304
Accrued balance, December 31, 2020	$	1,858	$	—	$	1,563	$	3,421
Charges incurred	140		—		—		140
Payments	(969)		—		—		(969)
Currency translation	(2)		—		31		29
Other adjustments(1)	(528)		—		(1,429)		(1,957)
Accrued balance, December 31, 2021	$	499	$	—	$	165	$	664

_______________________________________________

(1)    The estimated liabilities related to a prior year's facility closure restructuring were adjusted to actual amounts owed.

Strategic Transaction and Integration ExpensesWe incurred $19.8 million, $20.5 million and $72.2 million in strategic transaction and integration expenses in 2021, 2020 and 2019, respectively, which are included in restructuring, strategic transaction and integration expenses in our consolidated statement of operations. The strategic transaction and integration expenses during 2021 were related to integration costs associated with acquisitions, the Hospira Infusion Systems ("HIS") earn-out dispute with Pfizer, one-time costs incurred to comply with regulatory initiatives and transaction expenses incurred in connection with entering into a definitive agreement to acquire Smiths Medical 2020 Limited ("Smiths Medical") (see Note 17: Subsequent Events). The integration expenses during 2020 were related to the integration of HIS and included expenses for the migration of IT systems at our Austin facility. The strategic transaction and integration expenses during 2019 were primarily related to HIS, including a one-time strategic supply chain restructuring charge of $22.1 million, which reduced our contracted commitments to our third party manufacturer and charges related to our Pfizer separation costs, which included a $12.7 million non-cash write-off of related assets.